These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

395 related items for PubMed ID: 24056165

  • 1. Prevention of human papillomavirus (HPV) infection and cervical cancer in China: how does HPV vaccination bring about benefits to Chinese women?
    Liu X, Feng A, Cui Y, Tobe RG.
    Biosci Trends; 2013 Aug; 7(4):159-67. PubMed ID: 24056165
    [Abstract] [Full Text] [Related]

  • 2. [Human papillomavirus and carcinoma of the cervix vaccines against the human papillomavirus-promise of an efficacious prevention].
    Kohl I.
    Klin Mikrobiol Infekc Lek; 2006 Jun; 12(3):91-7. PubMed ID: 17051469
    [Abstract] [Full Text] [Related]

  • 3. Integrating human papillomavirus vaccination in cervical cancer control programmes.
    Franco EL, Coutlée F, Ferenczy A.
    Public Health Genomics; 2009 Jun; 12(5-6):352-61. PubMed ID: 19684447
    [Abstract] [Full Text] [Related]

  • 4. [Impact of vaccination against oncogenic human papillomavirus on the incidence and mortality of cervical cancer in Germany].
    Schneider A, Schwarz TF, Hammerschmidt T, Siebert U.
    Med Klin (Munich); 2007 Jul 15; 102(7):515-23. PubMed ID: 17634869
    [Abstract] [Full Text] [Related]

  • 5. A review of cross-protection against oncogenic HPV by an HPV-16/18 AS04-adjuvanted cervical cancer vaccine: importance of virological and clinical endpoints and implications for mass vaccination in cervical cancer prevention.
    Jenkins D.
    Gynecol Oncol; 2008 Sep 15; 110(3 Suppl 1):S18-25. PubMed ID: 18653221
    [Abstract] [Full Text] [Related]

  • 6. Implementation of human papillomavirus immunization in the developing world.
    Kane MA, Serrano B, de Sanjosé S, Wittet S.
    Vaccine; 2012 Nov 20; 30 Suppl 5():F192-200. PubMed ID: 23199963
    [Abstract] [Full Text] [Related]

  • 7. An extended cost-effectiveness analysis of publicly financed HPV vaccination to prevent cervical cancer in China.
    Levin CE, Sharma M, Olson Z, Verguet S, Shi JF, Wang SM, Qiao YL, Jamison DT, Kim JJ.
    Vaccine; 2015 Jun 04; 33(24):2830-41. PubMed ID: 25770785
    [Abstract] [Full Text] [Related]

  • 8. Epidemiology and prevention of human papillomavirus and cervical cancer in China and Mongolia.
    Shi JF, Qiao YL, Smith JS, Dondog B, Bao YP, Dai M, Clifford GM, Franceschi S.
    Vaccine; 2008 Aug 19; 26 Suppl 12():M53-9. PubMed ID: 18945414
    [Abstract] [Full Text] [Related]

  • 9. Recommendations for cervical cancer prevention in Asia Pacific.
    Garland SM, Cuzick J, Domingo EJ, Goldie SJ, Kim YT, Konno R, Parkin DM, Qiao YL, Sankaranarayanan R, Stern PL, Tay SK, Bosch FX.
    Vaccine; 2008 Aug 19; 26 Suppl 12():M89-98. PubMed ID: 18945418
    [Abstract] [Full Text] [Related]

  • 10. Long-term impact of human papillomavirus vaccination on infection rates, cervical abnormalities, and cancer incidence.
    Bogaards JA, Coupé VM, Xiridou M, Meijer CJ, Wallinga J, Berkhof J.
    Epidemiology; 2011 Jul 19; 22(4):505-15. PubMed ID: 21540743
    [Abstract] [Full Text] [Related]

  • 11. Benefits of vaccinating young adult women with a prophylactic quadrivalent human papillomavirus (types 6, 11, 16 and 18) vaccine.
    Monsonego J, Cortes J, Greppe C, Hampl M, Joura E, Singer A.
    Vaccine; 2010 Nov 29; 28(51):8065-72. PubMed ID: 20971114
    [Abstract] [Full Text] [Related]

  • 12. Human papillomavirus vaccines for the treatment of cervical cancer.
    Sin JI.
    Expert Rev Vaccines; 2006 Dec 29; 5(6):783-92. PubMed ID: 17184217
    [Abstract] [Full Text] [Related]

  • 13. Prophylactic human papillomavirus vaccination and primary prevention of cervical cancer: issues and challenges.
    Poljak M.
    Clin Microbiol Infect; 2012 Oct 29; 18 Suppl 5():64-9. PubMed ID: 22862799
    [Abstract] [Full Text] [Related]

  • 14. Human papillomavirus, cervical cancer, and the vaccines.
    Tovar JM, Bazaldua OV, Vargas L, Reile E.
    Postgrad Med; 2008 Jul 29; 120(2):79-84. PubMed ID: 18654072
    [Abstract] [Full Text] [Related]

  • 15. Review of current knowledge on HPV vaccination: an appendix to the European Guidelines for Quality Assurance in Cervical Cancer Screening.
    Arbyn M, Dillner J.
    J Clin Virol; 2007 Mar 29; 38(3):189-97. PubMed ID: 17258503
    [Abstract] [Full Text] [Related]

  • 16. Human Pappilomavirus (HPV) induced cancers and prevention by immunization.
    Khaliq SA, Shyum Naqvi SB, Fatima A.
    Pak J Pharm Sci; 2012 Oct 29; 25(4):763-72. PubMed ID: 23009992
    [Abstract] [Full Text] [Related]

  • 17. Human papilloma virus (HPV) prophylactic vaccination: challenges for public health and implications for screening.
    Adams M, Jasani B, Fiander A.
    Vaccine; 2007 Apr 20; 25(16):3007-13. PubMed ID: 17292517
    [Abstract] [Full Text] [Related]

  • 18. [Vaccination against cervical cancer and diseases caused by Human Papillomavirus].
    Bornstein J, Tuma R, Zarfati D, Ophir E.
    Harefuah; 2007 Oct 20; 146(10):764-9, 814. PubMed ID: 17990391
    [Abstract] [Full Text] [Related]

  • 19. The role of the human papillomavirus (HPV) vaccine in developing countries.
    Kling M, Zeichner JA.
    Int J Dermatol; 2010 Apr 20; 49(4):377-9. PubMed ID: 20465688
    [Abstract] [Full Text] [Related]

  • 20. Cost-effectiveness analysis of a quadrivalent human papilloma virus vaccine in Mexico.
    Reynales-Shigematsu LM, Rodrigues ER, Lazcano-Ponce E.
    Arch Med Res; 2009 Aug 20; 40(6):503-13. PubMed ID: 19853192
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 20.